Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome
1 other identifier
expanded_access
N/A
1 country
1
Brief Summary
Expanded access to Stiripentol for patients with Dravet Syndrome.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 7, 2013
CompletedFirst Posted
Study publicly available on registry
November 14, 2013
CompletedJanuary 23, 2026
January 1, 2026
November 7, 2013
January 21, 2026
Conditions
Interventions
Eligibility Criteria
You may qualify if:
- months and older
- Diagnosis of Dravet Syndrome with intractable seizures
You may not qualify if:
- Hypersensitivity to the active substance or to any of the excipients
- Past history of psychoses in the form of episodes of delirium
- Impaired hepatic and/or renal function, defined as creatinine \>2 and/or transaminase \>4xULN
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- expanded access
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 7, 2013
First Posted
November 14, 2013
Last Updated
January 23, 2026
Record last verified: 2026-01